Cytiva v. JSR Corp: Federal Circuit Splits Decision on Protein A Chromatography Patent
Cytiva Bioprocess R&D AB brought an infringement action against JSR Corporation and JSR Life Sciences LLC over US10343142B2, a patent covering Protein A-derived chromatography ligands central to biopharmaceutical antibody purification. After 497 days, the Federal Circuit issued a mixed ruling — affirming in part and reversing in part — a split outcome that leaves the commercial stakes unresolved for neither party.
A split Federal Circuit ruling on a key biopharmaceutical purification patent
Cytiva Bioprocess R&D AB, a GE Healthcare Life Sciences spin-off and leading supplier of bioprocessing consumables, filed Case No. 23-2193 on 26 July 2023 at the Court of Appeals for the Federal Circuit. The dispute centres on US10343142B2, which claims chromatography ligands incorporating domain C from Staphylococcus aureus Protein A — a foundational technology in the industrial purification of monoclonal antibodies. Defendants JSR Corporation and its subsidiary JSR Life Sciences LLC are major producers of chromatography resins that compete directly in this market.
The Federal Circuit issued its judgment on 4 December 2024, ordering the appeal dismissed in part and the lower court decision affirmed-in-part and reversed-in-part. This hybrid outcome suggests that Cytiva prevailed on at least some claims while JSR successfully challenged others, though the precise scope of each surviving or overturned finding is not fully disclosed in the public docket. Part of the appeal was dismissed on procedural grounds, limiting the merits review to a subset of the contested issues.
The 497-day duration is consistent with technically complex biotechnology appeals at the Federal Circuit, where claim construction and scientific evidence review typically extend proceedings. The split result likely reflects genuine ambiguity in the claim scope of US10343142B2 relative to JSR’s product design. What remains unknown from the public record is whether any remand was ordered, the specific claims affirmed or reversed, and whether a damages or injunction question awaits resolution at the district level.
Filing to Appeal Dismissed in Part in 497 days
497 days — above the median for Federal Circuit patent appeals, which typically resolve in 12–18 months
Federal Circuit splits the verdict: what affirmed-in-part, reversed-in-part means
What ‘affirmed-in-part, reversed-in-part’ means at the Federal Circuit
A split Federal Circuit disposition means the appellate panel found no reversible error in some of the lower court’s rulings — those stand — while identifying legal or factual error in others, which are overturned. This is distinct from a clean affirmance: the mandate will specify which holdings survive and which do not, and the case may return to the district court for further proceedings on reversed portions.
Mixed appellate dispositionCytiva retains some protection but faces continued exposure
The partial affirmance confirms that at least a portion of Cytiva’s infringement or claim-validity arguments survived appellate scrutiny, preserving some enforceability for US10343142B2. However, the reversal of other findings limits the full scope of the win. Cytiva cannot treat this as a complete vindication — the reversed elements may reduce the remedies available or narrow the claims it can assert going forward.
Partial protection confirmedJSR wins on some grounds but does not escape the patent entirely
JSR Corporation and JSR Life Sciences LLC secured a reversal on at least part of the lower court’s findings against them, which typically signals success on claim construction, invalidity, or non-infringement for a subset of asserted claims. The partial dismissal of the appeal further limits the scope of Cytiva’s victory. That said, the affirmed portion means JSR still faces live patent exposure and cannot treat this outcome as full clearance for its chromatography products.
Partial win, ongoing exposureProtein A ligand IP remains contested — market uncertainty persists
Protein A chromatography is a multi-billion-dollar segment of the bioprocessing supply chain, underpinning monoclonal antibody manufacturing globally. A split ruling preserves competitive tension: Cytiva cannot use this judgment to effect a broad market exclusion, and JSR cannot claim unambiguous freedom to operate. Competing resin suppliers monitoring this space should note that the patent’s enforceability remains at least partially intact, and further district-level proceedings are plausible.
Market uncertainty continuesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Cytiva Bioprocess R & D, AB | Individual | Bioprocessing reagent supplier — holder of US10343142B2 (Protein A chromatography ligand)Search in Eureka ↗ |
| Defendant | JSR Corporation | Company | JSR Corporation and JSR Life Sciences LLC — chromatography resin manufacturersSearch in Eureka ↗ |
| Co-Defendant | Jsr Life Sciences, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | David M. Krinsky | Attorney | Counsel for Cytiva Bioprocess R & D, ABSearch in Eureka ↗ |
| Plaintiff law firm | Williams & Connolly LLP | Law Firm | Representing Cytiva Bioprocess R & D, ABSearch in Eureka ↗ |
| Defendant counsel | Eric William Dittmann Esq. | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Hiroyuki Hagiwara | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Isaac S. Ashkenazi Esq. | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Michael Wolfe | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Naveen Modi | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Phillip W. Citroen | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant counsel | Stephen Blake Kinnaird | Attorney | Counsel for JSR CorporationSearch in Eureka ↗ |
| Defendant law firm | Paul Hastings Foreign Law Joint Enterprise | Law Firm | Representing JSR CorporationSearch in Eureka ↗ |
| Defendant law firm | Paul Hastings LLP | Law Firm | Representing JSR CorporationSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s order — ‘AFFIRMED-IN-PART AND REVERSED-IN-PART’ — is a technically precise disposition indicating the appellate panel conducted a merits review of at least some issues, applying de novo review to claim construction and clear-error review to factual findings. The partial dismissal narrows the mandate’s reach. For Cytiva, the affirmed portion preserves enforceability of US10343142B2 on surviving claims; for JSR, the reversed portion removes at least one adverse lower-court finding. The commercial significance turns entirely on which specific claims or holdings fell into each category, which the public record does not fully disclose.
US10343142B2 — Protein A domain C chromatography ligand for antibody isolation
US10343142B2 protects a chromatography ligand comprising domain C from Staphylococcus aureus Protein A, engineered for use in affinity chromatography columns designed to isolate and purify antibodies — particularly monoclonal antibodies used in biopharmaceuticals. Filed under application number US16/189894, the patent sits at the intersection of protein engineering and bioprocessing, covering the molecular design of the binding domain rather than merely the resin carrier. This is a highly technical claim scope where small amino acid substitutions can determine whether a competitor’s product falls inside or outside the claims.
Protein A affinity chromatography is the dominant platform technology for mAb purification in commercial biomanufacturing, with global demand driven by the ongoing expansion of antibody-based therapeutics. Control of IP in this space — particularly around engineered domain C variants that offer improved alkaline stability or binding capacity — confers significant leverage over competing resin suppliers. Cytiva’s assertion of this patent against JSR, one of the few manufacturers with scale to compete globally, underscores the strategic value of even a partially enforced claim portfolio in this segment.
Should your team run an FTO against US10343142B2?
Any organisation developing, manufacturing, or commercialising Protein A-derived affinity chromatography resins or ligands — particularly those incorporating engineered variants of domain C — should treat US10343142B2 as an active clearance risk. The Federal Circuit’s partial affirmance confirms the patent has survived appellate challenge on at least some claims. This is directly relevant to resin manufacturers, mAb facility operators sourcing columns, and CDMOs specifying purification platforms. A freedom-to-operate analysis should map your specific ligand design against the affirmed claim scope.
PatSnap Eureka’s FTO Search Agent can rapidly identify the claim boundaries of US10343142B2, surface related continuation and family members, and flag design-around prior art in the Protein A engineering space. Given the split Federal Circuit outcome, understanding exactly which claims survived is essential before any product launch or supply agreement in this domain. Eureka can also monitor downstream district-court docket activity to alert you if remand proceedings reactivate damages exposure.
Run a freedom-to-operate analysis on US10343142B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit appeals in biopharmaceutical chromatography IP
Explore related Federal Circuit patent appeals involving affinity chromatography, Protein A ligand technology, and biopharmaceutical purification process IP.
What this case signals for the bioprocessing chromatography IP landscape
The Cytiva v. JSR split ruling highlights the difficulty of securing clean appellate victories in technically complex biopharmaceutical patent disputes.
Protein A chromatography IP is genuinely contested — no clear dominant holder
The split Federal Circuit outcome in Cytiva v. JSR confirms that US10343142B2’s claim scope is not straightforward. Companies developing or marketing Protein A-based affinity resins should treat this patent as live IP with uncertain but real enforceability, and should not assume the reversal-in-part extinguishes all risk.
Partial dismissal of the appeal signals procedural vulnerability in complex biotech cases
The fact that part of the appeal was dismissed — not decided on the merits — suggests that strategic framing of appellate issues matters as much as substantive patent law in this domain. Parties challenging or defending bioprocess patents at the Federal Circuit should scrutinise standing, issue preservation, and appeal scope before filing.
AB v JSR — key questions answered
The Federal Circuit issued a mixed ruling on 4 December 2024: affirmed-in-part and reversed-in-part, with part of the appeal dismissed. This means some lower court findings in the infringement action over US10343142B2 were upheld while others were overturned. Neither party secured a complete victory.
US10343142B2 covers a chromatography ligand comprising domain C from Staphylococcus aureus Protein A, used for antibody isolation in affinity chromatography. It is a core technology in monoclonal antibody purification for biopharmaceutical manufacturing, and the patent’s claim scope centres on engineered variants of this binding domain.
A partial affirmance means at least some of Cytiva’s claims or the lower court’s holdings in its favour survived Federal Circuit review and remain enforceable. The reversal-in-part removes other adverse findings against JSR. The commercial impact depends on which specific claims were affirmed, which the public record does not fully specify.
No. The Basis of Termination indicates part of the appeal was dismissed, meaning not all issues were addressed on the merits. Only the surviving portion of the appeal received the affirmed-in-part, reversed-in-part ruling. This partial dismissal may reflect procedural or standing issues on certain claims.
Cytiva was represented by David M. Krinsky of Williams & Connolly LLP. JSR Corporation and JSR Life Sciences LLC were represented by a team from Paul Hastings LLP including Naveen Modi, Eric William Dittmann, Stephen Blake Kinnaird, Isaac S. Ashkenazi, Phillip W. Citroen, Michael Wolfe, and Hiroyuki Hagiwara.
PatSnap Eureka searches patents and litigation data to answer instantly.